Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
[Guillain-Barré syndrome with dysphagia after frontal sinusitis.]
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate.
The Nuclear IκB Family Protein IκBNS Influences the Susceptibility to Experimental Autoimmune Encephalomyelitis in a Murine Model.
Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis.
Upregulation of voltage-gated Ca(2+) channels in mouse astrocytes infected with Theiler's murine encephalomyelitis virus (TMEV).
Recombinant Human Myelin-Associated Glycoprotein Promoter Drives Selective AAV-Mediated Transgene Expression in Oligodendrocytes.
Carer quality of life and experiences of health services: a cross-sectional survey across three neurological conditions.
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.
Negative work events and accommodations in employed multiple sclerosis patients.
[Epidemiology of neuromyelitis optica].
Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats.
Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: "PT2".
Acute transverse myelitis in a child with lyme disease and a review of literature.
Next-Generation Sequencing Identifies MicroRNAs that Associate with Pathogenic Autoimmune Neuroinflammation in Rats.
Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3.
The Increasing Prevalence of Multiple Sclerosis in New Zealand.
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.
ASP4058, a Novel Agonist for Sphingosine 1-Phosphate Receptors 1 and 5, Ameliorates Rodent Experimental Autoimmune Encephalomyelitis with a Favorable Safety Profile.
Relationship between Sleep Quality and Quality of Life in Patients with Multiple Sclerosis.
Trefoil factor 3 shows anti-inflammatory effects on activated microglia.
High-throughput sequencing of immune repertoires in multiple sclerosis.
Increased apoptosis and hypomyelination in cerebral white matter of macular mutant mouse brain.
Commentary on: "Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss", by G. R. W. Moore, et al. in J Neurol (2008) 255: DOI 10.1007/s00415-008-0002-z.
Time to target brain atrophy and neurodegeneration in multiple sclerosis.
Pages
« first
‹ previous
…
632
633
634
635
636
637
638
639
640
…
next ›
last »